Unilife Corp

Unilife — Q3 FY2014 Earnings Presentation

13 slides from Unilife's earnings presentation, May 14, 2014

  1. Slide 1: Fiscal Year 2014 3rd Quarter Earnings Call

    Exhibit 99.2 rd FiscalYear20143 QuarterEarnings Call May 12,2014

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    CautionaryNote RegardingForward-LookingStatements Thispresentationcontainsforward lookingstatementsunderthe safeharbor provisionsof the USsecuritieslaws.Theseforward-lookingstatementsarebased on management’sbeliefsandassumptionsandon informationcurrentlyavailable to our management. Ourmanagementbeli

  3. Slide 3: Opening Comments

    Opening Comments $22.6MM in cash receipts from customers during the first nine months of FY 2014, with $10.9MM during Current Quarter $60MM debt financing with OrbiMed Generating cash receipts from ten ongoing customer programs, including several wearable injector programs Clear pathway to profitabi

  4. Slide 4: Participating in Large, Growing Markets

    Participating in Large, Growing Markets Market Segment Market Size* Market Trends / Unmet Needs Position of Unilife • Needlestick safety compliance. • Broad, customizable platform for all • $2B market Prefilled Syringes • High-performance biologics prefilled drugs, biologics and vaccines • 13.5% CAG

  5. Slide 5: Unilife is Much Like an Annuity Business Model

    Unilife is Much Like an Annuity Business Model Differentiated devices become part of the regulatory drug label Long-term supply contracts that ensure continuity of supply Each supply contract provides recurring annual revenue with intrinsic growth year over year New customers increase revenue and ra

  6. Slide 6: Scaling up for Existing and New Programs

    Scaling up for Existing and New Programs Ten ongoing customer programs as of March 31, 2014 Expanding operational infrastructure and cleanrooms Unifill ® platform of prefilled syringes Capacity for existing line largely sold or reserved for customers Additional lines on order for other Unifill produ

  7. Slide 7: OrbiMed Debt Financing

    OrbiMed Debt Financing $60MM debt financing with OrbiMed, the world’s largest dedicated healthcare investor $40MM received by Unilife to-date Unilife has the option to receive two extra tranches of $10MM each in December 2014 and June 2015* Interest only payments of approximately $1MM per quarter Ca

  8. Slide 8: Cash Receipts from Customers

    Cash Receipts from Customers 8

  9. Slide 9: Net Operating Cash Flow Loss

    Net Operating Cash Flow Loss 9

  10. Slide 10: Financial Results for Third Quarter of Fiscal 2014

    Financial Results for Third Quarter of Fiscal 2014 Revenue of $1.4MM* Deferred revenue increased by $8.3MM to $18.4MM $39.7MM of total cash and cash equivalents including restricted cash as of March 31, 2014 Three Months Ended Nine Months Ended March 31, March 31, 2014 2013 2014 2013 Revenues $1.4MM

  11. Slide 11: Fiscal Year 2014 Full Year Guidance

    Fiscal Year 2014 Full Year Guidance Expected recognized revenue for FY 2014 to be in range of $12MM - $15MM Commercial sales to begin comprising larger share of revenue from FY 2015 onwards 11

  12. Slide 12: Closing Statements

    Closing Statements Increasing cash position via cash receipts and OrbiMed deal Increasing base of pharmaceutical and biotech customers Increasing number of customer programs with ten now ongoing and activity underway across all product platforms Increasing revenue with $12 - $15MM target for FY 2014

  13. Slide 13: Questions

    Questions

Unilife — Q3 FY2014 Earnings Presentation on 6ix